CN116867788A - 4-氨基喹唑啉化合物 - Google Patents

4-氨基喹唑啉化合物 Download PDF

Info

Publication number
CN116867788A
CN116867788A CN202280014859.0A CN202280014859A CN116867788A CN 116867788 A CN116867788 A CN 116867788A CN 202280014859 A CN202280014859 A CN 202280014859A CN 116867788 A CN116867788 A CN 116867788A
Authority
CN
China
Prior art keywords
methyl
group
cyclopropyl
oxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280014859.0A
Other languages
English (en)
Chinese (zh)
Inventor
川口贤一
仓本和幸
今泉智祯
森川贵裕
奥村光晶
今田直
河南英次
佐藤亮
关阳平
滨口寿雄
石冈裕贵
福留裕树
栗胁生实
长岛建之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CN116867788A publication Critical patent/CN116867788A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280014859.0A 2021-02-15 2022-02-14 4-氨基喹唑啉化合物 Pending CN116867788A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
JP2021-021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
CN116867788A true CN116867788A (zh) 2023-10-10

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280014859.0A Pending CN116867788A (zh) 2021-02-15 2022-02-14 4-氨基喹唑啉化合物

Country Status (12)

Country Link
US (1) US20240150366A1 (https=)
EP (1) EP4293025B1 (https=)
JP (1) JP7725511B2 (https=)
KR (1) KR20230145360A (https=)
CN (1) CN116867788A (https=)
AU (1) AU2022219651A1 (https=)
CA (1) CA3211110A1 (https=)
ES (1) ES3054794T3 (https=)
MX (1) MX2023009520A (https=)
PL (1) PL4293025T3 (https=)
SA (1) SA523450286B1 (https=)
WO (1) WO2022173033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008849A (es) 2022-01-21 2024-07-25 Usynova Pharmaceuticals Ltd Compuestos de benzopirimidina y uso de estos.
AU2023231912A1 (en) * 2022-03-11 2024-08-15 Astellas Pharma Inc. Heterocyclic compound for inducing degradation of g12d mutant kras protein
JP7733274B1 (ja) * 2022-08-12 2025-09-02 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
AR130192A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden quimioterapia
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) * 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Also Published As

Publication number Publication date
EP4293025A4 (en) 2025-02-26
SA523450286B1 (ar) 2024-06-12
AU2022219651A1 (en) 2023-09-07
US20240150366A1 (en) 2024-05-09
MX2023009520A (es) 2023-08-24
EP4293025B1 (en) 2025-10-29
JP7725511B2 (ja) 2025-08-19
EP4293025C0 (en) 2025-10-29
JPWO2022173033A1 (https=) 2022-08-18
PL4293025T3 (pl) 2026-02-16
WO2022173033A1 (ja) 2022-08-18
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
ES3054794T3 (en) 2026-02-06
KR20230145360A (ko) 2023-10-17

Similar Documents

Publication Publication Date Title
JP7725511B2 (ja) ４－アミノキナゾリン化合物
CN116848120B (zh) 用于诱导g12d突变kras蛋白分解的喹唑啉化合物
CN115956080B (zh) 双环化合物，包含其的组合物及其应用
US11447492B2 (en) ERBB receptor inhibitors
JP6587116B2 (ja) キナゾリン化合物
JP6776446B2 (ja) Ｒｅｔキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリジン化合物
US20250263424A1 (en) Kras inhibitors
CA3255513A1 (en) HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
CN119604495A (zh) 用于诱导g12v突变kras蛋白分解的杂环化合物
JP2025523624A (ja) がんの治療のための方法
WO2023150394A1 (en) Methods for treatment of cancer
KR20210022055A (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
JP7724392B1 (ja) Ｋｒａｓタンパクの分解を誘導するための複素環化合物
JP7733274B1 (ja) Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
WO2021113492A1 (en) Cyclic compounds and methods of using same
CN117242074A (zh) Kras g12d抑制剂
CN117177976A (zh) Kras抑制剂
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
WO2025059027A1 (en) Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
JP2023541047A (ja) がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination